TY - STD TI - Office for National statistics: Cancer Statistics Registrations, England (Series MB1). 2011. No. 42. http://www.ons.gov.uk/ons/rel/vsob1/cancer-statistics-registrations%2D-england-%2Dseries-mb1-/no%2D-42%2D-2011/index.html. Accessed 6 June 2016. UR - http://www.ons.gov.uk/ons/rel/vsob1/cancer-statistics-registrations%2D-england-%2Dseries-mb1-/no%2D-42%2D-2011/index.html ID - ref1 ER - TY - JOUR AU - Morgan, G. J. PY - 2011 DA - 2011// TI - Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation JO - Blood VL - 118 UR - https://doi.org/10.1182/blood-2011-02-338665 DO - 10.1182/blood-2011-02-338665 ID - Morgan2011 ER - TY - JOUR AU - Cook, G. PY - 2014 DA - 2014// TI - High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70245-1 DO - 10.1016/S1470-2045(14)70245-1 ID - Cook2014 ER - TY - JOUR AU - Cook, G. PY - 2016 DA - 2016// TI - The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial JO - Lancet Haematol VL - 3 UR - https://doi.org/10.1016/S2352-3026(16)30049-7 DO - 10.1016/S2352-3026(16)30049-7 ID - Cook2016 ER - TY - STD TI - Cook G, Kirkland K, Pearce R. SBMT 5th report to the specialist commissioners. The outcome of haematopoietic stem cell transplantation: an analysis of registry data for UK transplants performed 2006–2011 and a detailed analysis of transplant activity and outcomes in 2012. London: British Society of Bone Marrow Transplant; 2014. ID - ref5 ER - TY - JOUR AU - Laubach, J. PY - 2016 DA - 2016// TI - Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group JO - Leukemia VL - 30 UR - https://doi.org/10.1038/leu.2015.356 DO - 10.1038/leu.2015.356 ID - Laubach2016 ER - TY - BOOK PY - 2016 DA - 2016// TI - NICE guideline [NG35] PB - diagnosis and management CY - Myeloma ID - ref7 ER - TY - JOUR AU - Mohty, M. PY - 2015 DA - 2015// TI - Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand? JO - Bone Marrow Transplant VL - 50 UR - https://doi.org/10.1038/bmt.2015.83 DO - 10.1038/bmt.2015.83 ID - Mohty2015 ER - TY - JOUR AU - Cook, G. PY - 2015 DA - 2015// TI - Re-invigorating rather than re-inventing the wheel: augmenting the impact of salvage autologous stem cell transplantation for multiple myeloma in the era of novel agents JO - Bone Marrow Transplant VL - 50 UR - https://doi.org/10.1038/bmt.2015.175 DO - 10.1038/bmt.2015.175 ID - Cook2015 ER - TY - BOOK PY - 2012 DA - 2012// TI - VELCADE (bortezomib) for injection [package insert] PB - Millenium Pharmaceuticals CY - Cambridge ID - ref10 ER - TY - JOUR AU - Assouline, S. E. PY - 2014 DA - 2014// TI - Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma JO - Blood Cancer J VL - 4 UR - https://doi.org/10.1038/bcj.2014.71 DO - 10.1038/bcj.2014.71 ID - Assouline2014 ER - TY - JOUR AU - Offidani, M. PY - 2014 DA - 2014// TI - An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma JO - Onco Targets Ther VL - 7 UR - https://doi.org/10.2147/OTT.S49187 DO - 10.2147/OTT.S49187 ID - Offidani2014 ER - TY - JOUR AU - Richardson, P. G. PY - 2014 DA - 2014// TI - Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2014-01-548826 DO - 10.1182/blood-2014-01-548826 ID - Richardson2014 ER - TY - JOUR AU - Kumar, S. K. PY - 2014 DA - 2014// TI - Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)71125-8 DO - 10.1016/S1470-2045(14)71125-8 ID - Kumar2014 ER - TY - JOUR AU - Moreau, P. PY - 2016 DA - 2016// TI - Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma JO - N Engl J Med VL - 374 UR - https://doi.org/10.1056/NEJMoa1516282 DO - 10.1056/NEJMoa1516282 ID - Moreau2016 ER - TY - JOUR AU - Baumann, P. PY - 2008 DA - 2008// TI - Alkylating agents induce activation of NFκB in multiple myeloma cells JO - Leuk Res VL - 32 UR - https://doi.org/10.1016/j.leukres.2007.11.015 DO - 10.1016/j.leukres.2007.11.015 ID - Baumann2008 ER - TY - JOUR AU - Mitsiades, N. PY - 2003 DA - 2003// TI - The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications JO - Blood VL - 101 UR - https://doi.org/10.1182/blood-2002-06-1768 DO - 10.1182/blood-2002-06-1768 ID - Mitsiades2003 ER - TY - JOUR AU - Doo, N. W. PY - 2013 DA - 2013// TI - Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma JO - Leuk Lymphoma VL - 54 UR - https://doi.org/10.3109/10428194.2012.746682 DO - 10.3109/10428194.2012.746682 ID - Doo2013 ER - TY - JOUR AU - Roussel, M. PY - 2010 DA - 2010// TI - Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM) JO - Blood VL - 115 UR - https://doi.org/10.1182/blood-2009-06-229658 DO - 10.1182/blood-2009-06-229658 ID - Roussel2010 ER - TY - JOUR AU - Child, J. A. PY - 2003 DA - 2003// TI - High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma JO - N Engl J Med VL - 348 UR - https://doi.org/10.1056/NEJMoa022340 DO - 10.1056/NEJMoa022340 ID - Child2003 ER - TY - JOUR AU - Dobson, A. J. AU - Gebski, V. J. PY - 1986 DA - 1986// TI - Sample sizes for comparing 2 independent proportions using the continuity-corrected arc sine transformation JO - Underst Stat VL - 35 ID - Dobson1986 ER - TY - JOUR AU - Lakatos, E. AU - Lan, K. K. G. PY - 1992 DA - 1992// TI - A comparison of sample-size methods for the logrank statistic JO - Stat Med VL - 11 UR - https://doi.org/10.1002/sim.4780110205 DO - 10.1002/sim.4780110205 ID - Lakatos1992 ER - TY - JOUR AU - Nooka, A. K. PY - 2014 DA - 2014// TI - Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients JO - Leukemia VL - 28 UR - https://doi.org/10.1038/leu.2013.335 DO - 10.1038/leu.2013.335 ID - Nooka2014 ER - TY - JOUR AU - Sonneveld, P. PY - 2012 DA - 2012// TI - Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.39.6820 DO - 10.1200/JCO.2011.39.6820 ID - Sonneveld2012 ER - TY - JOUR AU - Palumbo, A. PY - 2015 DA - 2015// TI - Revised international staging system for multiple myeloma: a report from International Myeloma Working Group JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2015.61.2267 DO - 10.1200/JCO.2015.61.2267 ID - Palumbo2015 ER - TY - JOUR AU - Freidlin, B. AU - Korn, E. L. AU - Gray, R. PY - 2010 DA - 2010// TI - A general inefficacy interim monitoring rule for randomized clinical trials JO - Clin Trials VL - 7 UR - https://doi.org/10.1177/1740774510369019 DO - 10.1177/1740774510369019 ID - Freidlin2010 ER - TY - JOUR AU - O'Brien, P. C. AU - Fleming, T. R. PY - 1979 DA - 1979// TI - A multiple testing procedure for clinical trials JO - Biometrics VL - 35 UR - https://doi.org/10.2307/2530245 DO - 10.2307/2530245 ID - O'Brien1979 ER - TY - JOUR AU - Morris, T. C. M. PY - 2013 DA - 2013// TI - Patient perceptions of second transplants in myeloma: impact on recruitment in the British Society of Blood and Marrow Transplantation/UK Myeloma Forum Myeloma X Relapse (Intensive) Trial JO - Br J Haematol VL - 163 UR - https://doi.org/10.1111/bjh.12513 DO - 10.1111/bjh.12513 ID - Morris2013 ER -